Amcasertib

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

一种小分子抑制剂，通过靶向激酶来抑制 Nanog 和其他 CSC（癌症干细胞）途径。

A small-molecule inhibitor that inhibits Nanog and other CSC (cancer stem cells) pathways by targeting kinases; targets and inhibits one or more pathways involved in cancer stem cell survival, shows potential antineoplastic activity.Liver Cancer Phase 2 Clinical(In Vitro):Amcasertib (0-1μM; 48h) inhibits the NANOG and CD133 expression in PC-9/GR cells. Amcasertib also significantly suppresses the growth of PC-9/GR cells in a dose-dependent manner.

Amcasertib (0-1μM; 48h) inhibits the NANOG and CD133 expression in PC-9/GR cells. Amcasertib also significantly suppresses the growth of PC-9/GR cells in a dose-dependent manner. Cell Viability Assay Cell Line:PC-9/GR cell Concentration:0, 0.3125, 0.625, 1.25, 2.5, 5 and 10μM Incubation Time:48 hours Result:Suppressed the growth of PC-9/GR cells in a dose-dependent manner for 48?hours with a OD value decreased from over 1.5 to less than 0.2 (p

——

BBI-503

Others

Other Targets

Others

Cancer

Liver Cancer

1129403-56-0

539.691

C31H33N5O2S

>98% (HPLC)

DMSO: ≥ 30 mg/mL

O=C(C1=C(C)NC(/C=C2C(NC3=C/2C=C(C4=CSC(C5=CC=CC=C5)=N4)C=C3)=O)=C1C)NCCN(CC)CC

1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[[1,2-dihydro-2-oxo-5-(2-phenyl-4-thiazolyl)-3H-indol-3-ylidene]methyl]-2,4-dimethyl-

(-20℃)

With Ice Pack

≥ 2 years